{"name":"2272c12f-2bad-4f64-b1a9-1ee109abacee","sections":[{"uuid":"56ca46e4-a0dc-4f86-b565-c8e01b0b1d42","position":1,"styles":{"offsetDifference":0,"offsetTop":15,"offsetBottom":15,"containerWidth":1200},"gridGap":15,"container":1200,"hidden":false,"columns":[{"uuid":"6cf690c3-a0ba-4323-b983-54dc43b215a5","blocks":[{"uuid":"169a3e62-3129-40f5-b898-97bf075df4e9","styles":{},"content":{"html":"

Effective 12.02.2025 the following information on the below qualified investments will be amended:

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n	\n Trading symbol \n
\n Identification code \n	\n ISIN \n	\n Prior to 12.02.2025 \n	\n As of 12.02.2025 \n
\n BTAI \n	\n US09075P1057 \n	\n BTAI \n	\n BTAIold \n

"},"icon":{"key":null,"ref":null,"props":{},"_owner":null},"activeDefault":true,"eventKeyCodeExceptions":[46],"type":"NewEditor","name":"Editor"}],"width":12,"connector":false,"position":1}],"containerOffset":0}],"selection":[{"uuid":"169a3e62-3129-40f5-b898-97bf075df4e9","styles":{},"content":{"html":"

Effective 12.02.2025 the following information on the below qualified investments will be amended:

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n	\n Trading symbol \n
\n Identification code \n	\n ISIN \n	\n Prior to 12.02.2025 \n	\n As of 12.02.2025 \n
\n BTAI \n	\n US09075P1057 \n	\n BTAI \n	\n BTAIold \n

"},"icon":{"key":null,"ref":null,"props":{},"_owner":null},"activeDefault":true,"eventKeyCodeExceptions":[46],"type":"NewEditor","name":"Editor"}]}

On amending the information in respect of ordinary shares of BioXcel Therapeutics, Inc. (BTAI)